Journal
MOLECULAR PHARMACOLOGY
Volume 66, Issue 4, Pages 1029-1034Publisher
AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/mol.104.002287
Keywords
-
Categories
Funding
- NHLBI NIH HHS [HL-07829] Funding Source: Medline
- NIGMS NIH HHS [GM61454] Funding Source: Medline
- NINDS NIH HHS [NS41441] Funding Source: Medline
Ask authors/readers for more resources
Heterotrimeric G proteins of the G12 family regulate the Rho GTPase through RhoGEFs that contain an amino-terminal regulator of G protein signaling (RGS) domain (RGS-RhoGEFs). Direct regulation of the activity of RGS-RhoGEFs p115 or leukemia-associated RhoGEF (LARG) by Galpha(13) has previously been demonstrated. However, the precise biochemical mechanism by which Galpha(13) stimulates the RhoGEF activity of these proteins has not yet been well understood. Based on the crystal structure of Galpha(i1) in complex with RGS4, we mutated the Galpha(13) residue lysine 204 to alanine (Galpha(13) K204A) and characterized the effect of this mutation in its regulation of RGS-RhoGEFs p115 or LARG. Compared with wild-type Galpha(13), Galpha(13)K204A induced much less serum-response factor activation when expressed in HeLa cells. Recombinant Galpha(13) K204A exhibits normal function in terms of nucleotide binding, basal GTP hydrolysis, and formation of heterotrimer with betagamma. We found that lysine 204 of Galpha(13) is important for interaction with the RGS domain of p115 or LARG and for the GTPase-activating protein activity of these proteins. In addition, the K204A mutation of Galpha(13) impaired its regulation of the RhoGEF activity of p115 or LARG. We conclude that lysine 204 of Galpha(13) is important for interaction with RGS-RhoGEFs and is critically involved in the regulation of their activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available